Topical vs Oral Metronidazole After Benign Anorectal Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05038605 |
Recruitment Status :
Completed
First Posted : September 9, 2021
Last Update Posted : September 9, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
While some investigators found oral metronidazole to be effective in reducing pain after hemorrhoidectomy, other researchers did not find a significant analgesic effect of systemic metronidazole. On the other hand, topical application of metronidazole had more consistent favorable results as Ala et al documented a remarkable analgesic effect of topical metronidazole 10% after excisional hemorrhoidectomy which was in line with Nicholson and Armestrong who also concluded similar results.
No previous study compared the analgesic effect of topical and oral metronidazole after anorectal surgery. Therefore, the present trial was conducted to compare the impact of oral versus systemic metronidazole on pain and recovery after surgery for benign anorectal conditions.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hemorrhoids Anal Fissure Anal Fistula | Drug: Topical metronidazole Drug: oral metronidazole | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 108 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Care Provider, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Topical Versus Oral Metronidazole for Pain Relief After Surgery for Benign Anorectal Conditions; a Prospective Randomized Study |
Actual Study Start Date : | January 24, 2020 |
Actual Primary Completion Date : | January 30, 2021 |
Actual Study Completion Date : | March 1, 2021 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Topical metronidazole
Topical application of metronidazole cream on the anal verge after surgery
|
Drug: Topical metronidazole
Topical application of metronidazole cream on the anal verge every 8 hours after surgery |
Active Comparator: Oral metronidazole
oral metronidazole 500 mg tablets after surgery
|
Drug: oral metronidazole
Patients received oral metronidazole 500 mg tablets every 8 hours after surgery |
No Intervention: Control
No metronidazole was received
|
- Postoperative pain score [ Time Frame: at one day after surgery ]Pain was assessed using visual analogue scale form 0 to 10, higher score indicates worse pain
- Postoperative pain score [ Time Frame: at two days after surgery ]Pain was assessed using visual analogue scale form 0 to 10, higher score indicates worse pain
- Postoperative pain score [ Time Frame: at seven days after surgery ]Pain was assessed using visual analogue scale form 0 to 10, higher score indicates worse pain

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult patients of either sex aged below 70 years
- Underwent surgery for hemorrhoids, anal fissure, or simple anal fistula.
Exclusion Criteria:
- Grade I-II hemorrhoids.
- acute anal fissure.
- complex anal fistula
- perianal abscess
- perianal Crohn's disease
- malignancy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05038605
Egypt | |
Mansoura university hospital | |
Mansourah, Dakahlia, Egypt, 35516 |
Responsible Party: | Sameh Emile, Associate professor of surgery, Mansoura University |
ClinicalTrials.gov Identifier: | NCT05038605 |
Other Study ID Numbers: |
Mansoura2021 |
First Posted: | September 9, 2021 Key Record Dates |
Last Update Posted: | September 9, 2021 |
Last Verified: | August 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Hemorrhoids Rectal Fistula Fissure in Ano Fistula Pathological Conditions, Anatomical Rectal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Vascular Diseases |
Cardiovascular Diseases Intestinal Fistula Digestive System Fistula Anus Diseases Metronidazole Anti-Infective Agents Anti-Bacterial Agents Antiprotozoal Agents Antiparasitic Agents |